Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 181

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms

Schönberg, Kathrin, Rudolph, Janna, Vonnahme, Maria, Parampalli Yajnanarayana, Sowmya, Cornez, Isabelle, Hejazi, Maryam, Manser, Angela R., Uhrberg, Markus, Verbeek, Walter, Koschmieder, Steffen, Brümmendorf, Tim H., Brossart, Peter, Heine, Annkristin, Wolf, Dominik · 2015 · Cancer Research

Abstract

Ruxolitinib is a small-molecule inhibitor of the JAK kinases, which has been approved for the treatment of myelofibrosis, a rare myeloproliferative neoplasm (MPN), but clinical trials are also being conducted in inflammatory-driven solid tumors. Increased infection rates have been reported in ruxolitinib-treated patients, and natural killer (NK) cells are immune effector cells known to eliminate both virus-infected and malignant cells. On this basis, we sought to compare the effects of JAK inhibition on human NK cells in a cohort of 28 MPN patients with or without ruxolitinib treatment and 24 healthy individuals. NK cell analyses included cell frequency, receptor expression, proliferation, immune synapse formation, and cytokine signaling. We found a reduction in NK cell numbers in ruxolitinib-treated patients that was linked to the appearance of clinically relevant infections. This reduction was likely due to impaired maturation of NK cells, as reflected by an increased ratio in immature to mature NK cells. Notably, the endogenous functional defect of NK cells in MPN was further aggravated by ruxolitinib treatment. In vitro data paralleled these in vivo results, showing a reduction in cytokine-induced NK cell activation. Further, reduced killing activity was associated with an impaired capacity to form lytic synapses with NK target cells. Taken together, our findings offer compelling evidence that ruxolitinib impairs NK cell function in MPN patients, offering an explanation for increased infection rates and possible long-term side effects associated with ruxolitinib treatment. Cancer Res; 75(11); 2187–99. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-3198

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 181

Metadata

Authors
Schönberg, K., Rudolph, J., Vonnahme, M., Parampalli Yajnanarayana, S., Cornez, I., Hejazi, M., Manser, A. R., Uhrberg, M., Verbeek, W., Koschmieder, S., Brümmendorf, T. H., Brossart, P., Heine, A., & Wolf, D.
Venue
Cancer Research
Published
2015-05-31
Volume
75
Issue
11
Pages
2187-2199
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2054787206
Cited by
181
References
6
FWCI
10.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-3198
The paper
Schönberg, K., Rudolph, J., Vonnahme, M., Parampalli Yajnanarayana, S., Cornez, I., Hejazi, M., Manser, A. R., Uhrberg, M., Verbeek, W., Koschmieder, S., Brümmendorf, T. H., Brossart, P., Heine, A., & Wolf, D. (2015). JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-3198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.